Efficacy of combined peroxisome proliferator-activated receptor-α ligand and glucocorticoid therapy in a murine model of atopic dermatitis

Journal of Investigative Dermatology

Volumn 131, Issue 9, 2011, Pages 1845-1852

  Hatano, Yutaka ^a   Elias, Peter M ^b   Crumrine, Debra ^b   Feingold, Kenneth R ^b   Katagiri, Kazumoto ^a   Fujiwara, Sakuhei ^a  

^a OITA UNIVERSITY   (Japan)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOBETASOL PROPIONATE; FILAGGRIN; INVOLUCRIN; LORICRIN; OXAZOLONE; PIRINIXIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATOPIC DERMATITIS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HOMEOSTASIS; MOUSE; NONHUMAN; PERMEABILITY BARRIER; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 80051798789     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2011.144     Document Type: Article

References (33)

1. Aberg KM, Radek KA, Choi EH et al. (2007) Psychological stress down-regulates epidermal antimicrobial peptide expression and increases severity of cutaneous infections in mice. J Clin Invest 117:3339-49 (Pubitemid 350096990)
2. Amano T, Takeda T, Yano H et al. (2007) Olopatadine hydrochloride accelerates the recovery of skin barrier function in mice. Br J Dermatol 156:906-12 (Pubitemid 46642836)
3. Angelova-Fischer I, Bauer A, Hipler UC et al. (2005) The objective severity assessment of atopic dermatitis (OSAAD) score: validity, reliability and sensitivity in adult patients with atopic dermatitis. Br J Dermatol 153:767-73 (Pubitemid 41415903)
4. Ashida Y, Denda M, Hirao T (2001) Histamine H1 and H2 receptor antagonists accelerate skin barrier repair and prevent epidermal hyperplasia induced by barrier disruption in a dry environment. J Invest Dermatol 116:261-5 (Pubitemid 32173730)
5. Chamlin SL, Kao J, Frieden IJ et al. (2002) Ceramide-dominant barrier repair lipids alleviate childhood atopic dermatitis: changes in barrier function provide a sensitive indicator of disease activity. J Am Acad Dermatol 47:198-208
6. Cork MJ, Britton J, Butler L et al. (2003) Comparison of parent knowledge, therapy utilization and severity of atopic eczema before and after explanation and demonstration of topical therapies by a specialist dermatology nurse. Br J Dermatol 149:582-9 (Pubitemid 37281592)
7. Demerjian M, Choi EH, Man MQ et al. (2009) Activators of PPARs and LXR decrease the adverse effects of exogenous glucocorticoids on the epidermis. Exp Dermatol 18:643-9
8. Elias PM, Hatano Y, Williams ML (2008) Basis for the barrier abnormality in atopic dermatitis: "outside-inside-outside" pathogenic mechanisms. J Allergy Clin Immunol 121:1337-43
9. Fluhr JW, Man MQ, Hachem JP et al. (2009) Topical peroxisome proliferator activated receptor activators accelerate postnatal stratum corneum acidification. J Invest Dermatol 129:365-74
10. Fowler AJ, Sheu MY, Schmuth M et al. (2003) Liver X receptor activators display anti-inflammatory activity in irritant and allergic contact dermatitis models: liver-X-receptor-specific inhibition of inflammation and primary cytokine production. J Invest Dermatol 120:246-55 (Pubitemid 36513075)
11. Fukaya M (2000) Improvement of atopic dermatitis after discontinuation of topical corticosteroid treatment. Arch Dermatol 136:679-80 (Pubitemid 30304962)
12. Furue M, Terao H, Moroi Y et al. (2004) Dosage and adverse effects of topical tacrolimus and steroids in daily management of atopic dermatitis. J Dermatol 31:277-83 (Pubitemid 38590770)
13. Hatano Y, Man MQ, Uchida Y et al. (2009) Maintenance of an acidic stratum corneum prevents emergence of murine atopic dermatitis. J Invest Dermatol 129:1824-35
14. Hatano Y, Man MQ, Uchida Y et al. (2010) Murine atopic dermatitis responds to peroxisome proliferator-activated receptors alpha and beta/delta (but not gamma) and liver X receptor activators. J Allergy Clin Immunol 125:160-9
15. Hiratsuka S, Yoshida A, Ishioka C et al. (1996) Enhancement of in vitro spontaneous IgE production by topical steroids in patients with atopic dermatitis. J Allergy Clin Immunol 98:107-13 (Pubitemid 26289392)
16. Hou SY, Mitra AK, White SH et al. (1991) Membrane structures in normal and essential fatty acid-deficient stratum corneum: characterization by ruthenium tetroxide staining and X-ray diffraction. J Invest Dermatol 96:215-23
17. Kao JS, Fluhr JW, Man MQ et al. (2003) Short-term glucocorticoid treatment compromises both permeability homeostasis and stratum corneum integrity: inhibition of epidermal lipid synthesis accounts for functional abnormalities. J Invest Dermatol 120:456-64 (Pubitemid 36298433)
18. Kawakami T, Soma Y, Morita E et al. (2001) Safe and effective treatment of refractory facial lesions in atopic dermatitis using topical tacrolimus following corticosteroid discontinuation. Dermatology 203:32-7 (Pubitemid 32830528)
19. Kim M, Jung M, Hong SP et al. (2010) Topical calcineurin inhibitors compromise stratum corneum integrity, epidermal permeability and antimicrobial barrier function. Exp Dermatol 19:501-10
20. Komuves LG, Hanley K, Lefebre A et al. (2000a) Stimulation of PPARalpha promotes epidermal keratinocyte differentiation in vivo. J Invest Dermatol 115:353-60
21. Komuves LG, Hanley K, Man MQ et al. (2000b) Keratinocyte differentiation in hyperproliferative epidermis: topical application of PPARalpha activators restores tissue homeostasis. J Invest Dermatol 115:361-7
22. Kurahashi R, Hatano Y, Katagiri K (2008) IL-4 suppresses the recovery of cutaneous permeability barrier functions in vivo. J Invest Dermatol 128:1329-31 (Pubitemid 351543188)
23. Man MQ, Hatano Y, Lee SH et al. (2008) Characterization of a hapten-induced, murine model with multiple features of atopic dermatitis: structural, immunologic, and biochemical changes following single versus multiple oxazolone challenges. J Invest Dermatol 128:79-86 (Pubitemid 350249387)
24. Meurer M, Fölster-Holst R, Wozel G et al. (2002) Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study. Dermatology 205:271-7
25. Schacke H, Docke WD, Asadullah K (2002) Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 96:23-43 (Pubitemid 35346616)
26. Scharschmidt TC, Man MQ, Hatano Y et al. (2009) Filaggrin deficiency confers a paracellular barrier abnormality that reduces inflammatory thresholds to irritants and haptens. J Allergy Clin Immunol 124:496-506
27. Schmuth M, Jiang YJ, Dubrac S et al. (2008) Thematic review series: skin lipids. Peroxisome proliferators-activated receptors and liver X receptors in epidermal biology. J Lipid Res 49:499-509
28. Sheu MY, Fowler AJ, Kao J et al. (2002) Topical peroxisome proli-ferator activated receptor-alpha activators reduce inflammation inirritant and allergic contact dermatitis models. J Invest Dermatol 118:94-101 (Pubitemid 34107429)
29. Staumont-Salle D, Abboud G, Brenuchon C et al. (2008) Peroxisome proliferator-activated receptor alpha regulates skin inflammation and humoral response in atopic dermatitis. J Allergy Clin Immunol 121:962-8
30. Sugarman JL, Fluhr JW, Fowler AJ et al. (2003) The objective severity assessment of atopic dermatitis score: an objective measure using permeability barrier function and stratum corneum hydration with computer-assisted estimates for extent of disease. Arch Dermatol 139:1417-22 (Pubitemid 37433131)
31. Tamura T, Matsubara M, Amano T et al. (2008) Olopatadine ameliorates rat experimental cutaneous inflammation by improving skin barrier function. Pharmacology 81:118-26 (Pubitemid 351182686)
32. Tamura T, Matsubara M, Hasegawa K et al. (2005) Olopatadine hydro-chloride suppresses the rebound phenomenon after discontinuation of treatment with a topical steroid in mice with chronic contact hypersensitivity. Clin Exp Allergy 35:97-103 (Pubitemid 40188277)
33. Wirén K, Nohlgard C, Nyberg F et al. (2009) Treatment with a barrier-strengthening moisturizing cream delays relapse of atopic dermatitis: a prospective and randomized controlled clinical trial. J Eur Acad Dermatol Venereol 23:1267-72